Expression of ikaros isoform 6 in chinese children with acute lymphoblasticLeukemia

Journal of Pediatric Hematology/Oncology

Volumn 33, Issue 6, 2011, Pages 429-432

  Zhou, Fen ^a   Mei, Heng ^a   Jin, Runming ^a   Li, Xiaoqing ^a   Chen, Xiangjun ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

acute lymphoblastic leukemia; ALL; dominantnegative Ikaros isoform 6; nested RT PCR

Indexed keywords

BCR ABL PROTEIN; HOX PROTEIN; IKAROS 1 TRANSCRIPTION FACTOR; IKAROS 10 TRANSCRIPTION FACTOR; IKAROS 2 TRANSCRIPTION FACTOR; IKAROS 3 TRANSCRIPTION FACTOR; IKAROS 4 TRANSCRIPTION FACTOR; IKAROS 6 TRANSCRIPTION FACTOR; IKAROS 8 TRANSCRIPTION FACTOR; IKAROS 9 TRANSCRIPTION FACTOR; IKAROS TRANSCRIPTION FACTOR; MESSENGER RNA; UNCLASSIFIED DRUG;

ABL GENE; ACUTE LYMPHOBLASTIC LEUKEMIA; AF9 GENE; AGE; AML1 GENE; ARTICLE; B CELL LEUKEMIA; BCR GENE; CHILD; CHILDHOOD LEUKEMIA; CHINESE; CONTROLLED STUDY; E2A GENE; FEMALE; FG GENE; FUSION GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HOX11 GENE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MLL GENE; ONCOGENE; PBX1 GENE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SCHOOL CHILD; SEQUENCE ANALYSIS; T CELL LEUKEMIA; TEL GENE;

CHILD; CHINA; FEMALE; HUMANS; IKAROS TRANSCRIPTION FACTOR; MALE; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROTEIN ISOFORMS; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, MESSENGER;

EID: 80051743572     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318217f5f2     Document Type: Article

References (17)

1. Wang JH, Nichogiannopoulou A, Wu L, et al. Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity. 1996;5:537-549. (Pubitemid 27062064)
2. Winandy S, Wu P, Georgopoulos K. A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma. Cell. 1995;83:289-299.
3. Rebollo A, Schmitt C. Ikaros, Aiolos and Helios: Transcription regulators and lymphoid malignancies. Immunol Cell Biol. 2003;81:171-175. (Pubitemid 36649262)
4. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in Acute Lymphoblastic Leukemia. N Engl J Med. 2009;360:470-480.
5. Mullighan CG, Miller CB, Phillips LA, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453:110-114. (Pubitemid 351630327)
6. Iacobucci I, Lonetti A, Cilloni D, et al. Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high- throughput capillary electrophoresis sizing method. Haematologica. 2008;93:1814-1821.
7. Koipally J, Georgopoulos K. Molecular dissection of the repression circuitry of Ikaros. J Biol Chem. 2002;277: 27697-27705. (Pubitemid 34966713)
8. Tonnelle C, Imbert MC, Sainty D, et al. Overexpression of dominant-negative Ikaros 6 protein is restricted to a subset of B common adult acute lymphoblastic leukemias that express high levels of the CD34 antigen. Hematol J. 2003;4:104-109. (Pubitemid 36748512)
9. Kano G, Morimoto A, Takanashi M, et al. Ikaros dominant negative isoform (Ik6) induces IL-3-independent survival of murine pro-B lymphocytes by activating JAK-STAT and upregulating Bcl-xl levels. Leuk Lymphoma. 2008;49:965-973. (Pubitemid 351942752)
10. Sezaki N, Ishimaru F, Takata M, et al. Overexpression of the dominant-negative isoform of Ikaros confers resistance to dexamethasone induced and anti-IgM- induced apoptosis. Br J Haematol. 2003;121:165-169. (Pubitemid 36461284)
11. Stow P, Key L, Chen X, et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood. 2010;115:4657-4663.
12. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukemia. Lancet. 2008;371:1030-1043.
13. Rivera GK, Zhou Y, Hancock ML, et al. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer. 2005;103:368-376. (Pubitemid 40129297)
14. Wang YR, Jin RM, Xu JW, et al. Outcome of childhood acute lymphoblastic leukemia: A report of 121 patients treated at Wuhan Union Hospital of China. Chin Med J (Engl). 2008;121:469-472.
15. Luo XQ, Ke ZY, Huang LB, et al. High-risk childhood acute lymphoblastic leukemia in China: Factors influencing the treatment and outcome. Pediatr Blood Cancer. 2009; 52:191-195.
16. Luo XQ, Ke ZY, Guan XQ, et al. The comparison of outcome and cost of three protocols for childhood non-high risk acute lymphoblastic leukemia in China. Pediatr Blood Cancer. 2008;51:204-209.
17. Kuiper RP, Waanders E, van der Velden VH, et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia. 2010;24:1258-1264.